
News|Articles|February 4, 2025
FDA news in pediatrics: January 2025
Author(s)Patrick Campbell
A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.
Advertisement
Advertisement
Navigating the ever-evolving landscape of pediatric care means staying ahead of clinical developments, regulatory shifts, and therapeutic breakthroughs—each with the potential to reshape how we support children’s health. In the January 2025 FDA update from Contemporary Pediatrics, we highlight decisions that reflect both the complexity and promise of modern pediatrics, including new drug submissions, a pivotal ban on red No. 3 in food and ingested drugs, and an expanded clearance for a familiar face.
Related to this article

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.

In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.

Michael Pistiner, MD, discusses how pediatricians can support food allergy management in schools through accurate diagnosis, emergency plans, and education.

Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.

FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
Advertisement
Advertisement


